[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350819-105":59,"doc-detail-350819-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","urinary-biomarkers-in-urological-oncology-from-biological-origin-to-clinical-decision-making-a-narrative-review","Urinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making - A Narrative Review","","Urinary biomarkers are promising tools in urological oncology because urine can be collected non-invasively and repeatedly during diagnosis, treatment, and surveillance. Despite extensive biomarker discovery, routine adoption remains limited. Biomarker performance depends on more than analytical accuracy, including clinical decisions, urinary anatomical route, biological signal source, specimen fraction, and sampling timing and conditions. This review evaluates biomarkers across bladder cancer, UTUC, prostate cancer, and RCC using a biologically grounded, decision-oriented framework.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/urinary-biomarkers-in-urological-oncology-from-biological-origin-to-clinical-decision-making-a-narrative-review/350819/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/urinary-biomarkers-in-urological-oncology-from-biological-origin-to-clinical-decision-making-a-narrative-review/350819.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are urinary biomarkers considered attractive for urological oncology?","Question",{"text":113,"@type":114},"Urine can be collected non-invasively and repeatedly across diagnosis, treatment monitoring, and long-term surveillance, enabling longitudinal assessment with minimal patient burden.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What factors influence urinary biomarker performance beyond analytical accuracy?",{"text":118,"@type":114},"Clinical decision framing, anatomical route into urine, biological origin of the signal, specimen fraction, and sampling timing and conditions all shape biomarker performance.",{"name":120,"@type":111,"acceptedAnswer":121},"How should clinical translation of urinary biomarkers be evaluated?",{"text":122,"@type":114},"Translation should rely on decision-specific outcomes such as incremental value and net clinical benefit, rather than diagnostic accuracy or AUC alone.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350819,1790580393,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":24,"preview_urls":147},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Review  \nUrinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making—A Narrative Review  \nAliya Nurmukhanbetova 1, Kassymkhan Sultanbekov 2,*, Khussan Umurzakov 3,*, Zie Gassanov 3, Altyn Duisenbayeva 4, Alimkhan Talas 4, Lazzat Shaikenova 5 and Aidos Bolatov 6,7  \nAcademic Editor: ConsolatoM. Sergi  \nReceived: 10 July 2026  \nRevised: 15 August 2026  \nAccepted: 24 August 2026  \nPublished: 1 September 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 General Immunology Department, Asfendiyarov Kazakh National Medical University, Almaty 050054, Kazakhstan; [nurmukhanbetova.a@kaznmu.kz](nurmukhanbetova.a@kaznmu.kz)  \n2 Department of Public Health and Healthcare, South Kazakhstan Medical Academy, Shymkent 160019, Kazakhstan  \n3 Urooncology Center, Kazakh Institute of Oncology and Radiology, Almaty 050022, Kazakhstan; [ziegasanov@mail.ru](ziegasanov@mail.ru)  \n4 Department of General Medical Practice No. 2, Asfendiyarov Kazakh National Medical University, Almaty 050054, Kazakhstan; [d.altyn_zh@mail.ru](d.altyn_zh@mail.ru) (A.D.); [albergerectino@gmail.com](albergerectino@gmail.com) (A.T.)  \n5 Department of Clinical Disciplines, University of International Business Named After Kenzhegali Sagadiev, Almaty 050010, Kazakhstan; [lazzat.shaikenova1965@gmail.com](lazzat.shaikenova1965@gmail.com)  \n6 Shenzhen University Medical School, Shenzhen University, Shenzhen 518037, China; [bolatovaidos@gmail.com](bolatovaidos@gmail.com)  \n7 Department of Science,“University Medical Center” Corporate Fund, Astana 010000, Kazakhstan  \n* Correspondence: [k.sultanbekov@skma.edu.kz](k.sultanbekov@skma.edu.kz) (K.S.); [has.hus@mail.ru](has.hus@mail.ru) (K.U.); Tel.: +7-701-718-3726 (K.S.); +7-777-357-5774 (K.U.)  \nAbstract  \nUrinary biomarkers are promising tools in urological oncology because urine can be collected non-invasively and repeatedly during diagnosis, treatment, and surveillance. Despite extensive biomarker discovery, their adoption in routine practice remains limited. Biomarker performance depends not only on analytical accuracy but also on the clinical decision, anatomical route into urine, biological source of the signal, specimen fraction, and timing and conditions of sampling. This review evaluates urinary biomarkers across bladder cancer, upper-tract urothelial carcinoma, prostate cancer, and renal cell carcinoma using a biologically grounded, decision-oriented framework. It considers tumor-derived nucleic acids, epigenetic alterations, proteins, immune and inflammatory mediators, extracellular vesicles, metabolites, microbiome-associated signals, and multiparametric models. Bladder cancer represents the most anatomically direct and clinically mature setting, with potential applications in hematuria evaluation, cystoscopy triage, recurrence surveillance, molecular residual disease assessment, and monitoring of response to bacillus Calmette– Guérin therapy. In upper-tract urothelial carcinoma, distinguishing voided from selectively collected urine is essential because dilution, transit, obstruction, and limited localization affect interpretation. Prostate urine assays are best positioned for biopsy triage and refinement of active surveillance rather than general population screening. Renal cell carcinoma biomarkers remain exploratory because the sources and mechanisms of urinary signal release are insufficiently resolved. Clinical translation should be assessed using decisionspecific outcomes, including incremental value, calibration, net clinical benefit, procedures avoided, significant cancers missed, reproducibility, and feasibility, rather than diagnostic accuracy or area under the receiver operating characteristic curve alone.  \nKeywords: urinary biomarkers; liquid biopsy; bladder cancer; upper-tract urothelial carcinoma; prostate cancer","cbCaibWOr075Y0iF","https://ap.wps.com/l/cbCaibWOr075Y0iF","pdf",6849669,47,"English","# 1. Introduction: Why Urinary Biomarkers Remain Difficult to Translate into Clinical Oncology\n## Translation gap: regulatory approval vs limited clinical impact","[{\"question\":\"Why are urinary biomarkers considered attractive for urological oncology?\",\"answer\":\"Urine can be collected non-invasively and repeatedly across diagnosis, treatment monitoring, and long-term surveillance, enabling longitudinal assessment with minimal patient burden.\"},{\"question\":\"What factors influence urinary biomarker performance beyond analytical accuracy?\",\"answer\":\"Clinical decision framing, anatomical route into urine, biological origin of the signal, specimen fraction, and sampling timing and conditions all shape biomarker performance.\"},{\"question\":\"How should clinical translation of urinary biomarkers be evaluated?\",\"answer\":\"Translation should rely on decision-specific outcomes such as incremental value and net clinical benefit, rather than diagnostic accuracy or AUC alone.\"}]","Urinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making - A Narrative Review | PDF",1790091293,118,[148,152,156,160,164],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2a8c37b927dbd2a7684d8734cd37d53.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f07dcb3a6a1f49889abf3e83e7c26b7a.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a00bc024817f9928770ec34491e617c1.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d01ce1f06aa330940bbb6f7459d7ae4.webp",980,1385,{"page_no":24,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e008d5fc66d6ea990d8a7d23a4d4d185.webp",979,1384]